Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Why Alcon (SWX:ALC) is on investors' radar today
Alcon (SWX:ALC) has drawn attention after recent trading left the stock with a year-to-date return of about an 8% decline and a one-year total return of about a 28% decline.
See our latest analysis for Alcon.
The share price is currently at CHF58.22, with a 30-day share price return of about a 3.5% decline and a 90-day share price return of about a 6% decline. The 1-year total shareholder return of about a 28% decline suggests momentum has been fading over a longer horizon.
If Alcon's recent moves have you reassessing your watchlist, it can help to see what else is out there and compare with 125 healthcare AI stocks .
With Alcon trading at CHF58.22 and indications of a discount to some valuation estimates, a key question for you is whether this weakness represents a potential entry point or whether the market is already pricing in future growth.
Most Popular Narrative: 26.3% Undervalued
Alcon's most followed narrative pegs fair value at CHF79.02 versus the last close of CHF58.22, which frames the recent share price weakness in a different light.
Accelerated new product launches including Unity VCS (next gen surgical platform), PanOptix Pro (premium IOL), Tryptyr (first in class dry eye Rx), Precision7 (novel contact lens), and recent pipeline accretive M&A (STAAR, LumiThera, Voyager) provide significant near
Want to see how this product pipeline is expected to translate into higher sales, fatter margins, and a richer earnings multiple over time? The narrative lays out a full set of revenue, profitability and valuation assumptions that connect these launches and acquisitions to that CHF79.02 fair value mark.
Result: Fair Value of CHF79.02 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you should weigh that upside case against risks such as sustained cataract procedure softness and pressure from rival IOL and contact lens offerings, which could limit the payoff from new launches.
Find out about the key risks to this Alcon narrative.
Another View: Valuation Through The P/E Lens
So far, the fair value story for Alcon has leaned on cash flow based estimates that point to a discount. The P/E picture tells something different. At 37x earnings, Alcon trades well above the European Medical Equipment industry on 23.7x, the peer average on 23.5x, and even its own 32.6x fair ratio. This suggests investors are already paying a premium. The question is whether you think the company can earn into that premium or if it leaves less room for error.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment mixed across valuation methods, it helps to move quickly, review the data points that matter most, and shape your own conviction. To see what investors view as the key positives supporting the stock, check out the 3 key rewards
Looking for more investment ideas?
If Alcon is on your radar, do not stop here. Broaden your watchlist now and give yourself more options before the next big move passes by.
-
Target potential mispricings by scanning a curated set of 248 high quality undervalued stocks that combine quality fundamentals with appealing price tags.
-
Strengthen your focus on resilience by checking out 306 resilient stocks with low risk scores that score well on financial stability and lower risk profiles.
-
Get ahead of the crowd by reviewing a screener containing 571 high quality undiscovered gems that most investors may not be looking at yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ALC.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
